The Swedish Medical Products Agency Approves Medivir’s Xerclear

The Swedish Medical Products Agency has now approved Xerclear for treatment of cold sores. It is a topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear will be available from pharmacies in the first half of 2010.

Johan Harmenberg, associate professor of virology and one of the originators of Xerclear, said: “Xerclear has two active ingredients with antiviral and anti-inflammatory effects. With early treatment onset, many people can completely avoid herpes cold sores. Xerclear is a completely new concept for treating labial herpes, which has also been demonstrated to have a far superior therapeutic effect for patients. If the occurrence of cold sores can be prevented, this is obviously a great relief for patients with repeated labial herpes.”

Earlier this year, Xerclear (acyclovir 50mg/g + hydrocortisone 10mg/g) was approved in the US and Europe. The Swedish Medical Products Agency has now issued its final statement of opinion, implying that Xerclear will be released in Sweden, with 5g tubes available on prescription in the first quarter of 2010. The over-the-counter 2g tube will be available in the second quarter of 2010.